These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 28522586)

  • 21. Effective anti-angiogenic therapy of established tumors in mice by naked anti-human endoglin (CD105) antibody: differences in growth rate and therapeutic response between tumors growing at different sites.
    Tsujie M; Uneda S; Tsai H; Seon BK
    Int J Oncol; 2006 Nov; 29(5):1087-94. PubMed ID: 17016638
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanistic target of rapamycin small interfering RNA and rapamycin synergistically inhibit tumour growth in a mouse xenograft model of human oesophageal carcinoma.
    Sun MM; Zhang MZ; Chen Y; Li SL; Zhang W; Ya GW; Chen KS
    J Int Med Res; 2012; 40(5):1636-43. PubMed ID: 23206445
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of combined inhibition of MEK and mTOR on downstream signaling and tumor growth in pancreatic cancer xenograft models.
    Chang Q; Chen E; Hedley DW
    Cancer Biol Ther; 2009 Oct; 8(20):1893-901. PubMed ID: 20009539
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature.
    Davis PD; Dougherty GJ; Blakey DC; Galbraith SM; Tozer GM; Holder AL; Naylor MA; Nolan J; Stratford MR; Chaplin DJ; Hill SA
    Cancer Res; 2002 Dec; 62(24):7247-53. PubMed ID: 12499266
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A humanized immunoenzyme with enhanced activity for glucuronide prodrug activation in the tumor microenvironment.
    Chen KC; Wu SY; Leu YL; Prijovich ZM; Chen BM; Wang HE; Cheng TL; Roffler SR
    Bioconjug Chem; 2011 May; 22(5):938-48. PubMed ID: 21443266
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined enzyme/prodrug treatment by genetically engineered AT-MSC exerts synergy and inhibits growth of MDA-MB-231 induced lung metastases.
    Matuskova M; Kozovska Z; Toro L; Durinikova E; Tyciakova S; Cierna Z; Bohovic R; Kucerova L
    J Exp Clin Cancer Res; 2015 Apr; 34(1):33. PubMed ID: 25884597
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Collaboration between hepatic and intratumoral prodrug activation in a P450 prodrug-activation gene therapy model for cancer treatment.
    Ma J; Waxman DJ
    Mol Cancer Ther; 2007 Nov; 6(11):2879-90. PubMed ID: 17989319
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting Phosphatidylinositol 3-Kinase Signaling Pathway for Therapeutic Enhancement of Vascular-Targeted Photodynamic Therapy.
    Kraus D; Palasuberniam P; Chen B
    Mol Cancer Ther; 2017 Nov; 16(11):2422-2431. PubMed ID: 28835385
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RGD delivery of truncated coagulase to tumor vasculature affords local thrombotic activity to induce infarction of tumors in mice.
    Jahanban-Esfahlan R; Seidi K; Monhemi H; Adli ADF; Minofar B; Zare P; Farajzadeh D; Farajnia S; Behzadi R; Abbasi MM; Zarghami N; Javaheri T
    Sci Rep; 2017 Aug; 7(1):8126. PubMed ID: 28811469
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy.
    Munoz R; Man S; Shaked Y; Lee CR; Wong J; Francia G; Kerbel RS
    Cancer Res; 2006 Apr; 66(7):3386-91. PubMed ID: 16585158
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene.
    Chen L; Waxman DJ; Chen D; Kufe DW
    Cancer Res; 1996 Mar; 56(6):1331-40. PubMed ID: 8640822
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of mTOR inhibition alone or combined with MEK inhibitors on brain metastasis: an in vivo analysis in triple-negative breast cancer models.
    Zhao H; Cui K; Nie F; Wang L; Brandl MB; Jin G; Li F; Mao Y; Xue Z; Rodriguez A; Chang J; Wong ST
    Breast Cancer Res Treat; 2012 Jan; 131(2):425-36. PubMed ID: 21394501
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A monoclonal antibody that binds anionic phospholipids on tumor blood vessels enhances the antitumor effect of docetaxel on human breast tumors in mice.
    Huang X; Bennett M; Thorpe PE
    Cancer Res; 2005 May; 65(10):4408-16. PubMed ID: 15899833
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chimeric TNT-3/human beta-glucuronidase fusion proteins for antibody-directed enzyme prodrug therapy (ADEPT).
    Biela BH; Khawli LA; Hu P; Epstein AL
    Cancer Biother Radiopharm; 2003 Jun; 18(3):339-53. PubMed ID: 12954121
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An HRE-Binding Py-Im Polyamide Impairs Hypoxic Signaling in Tumors.
    Szablowski JO; Raskatov JA; Dervan PB
    Mol Cancer Ther; 2016 Apr; 15(4):608-17. PubMed ID: 26719577
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiangiogenesis enhances intratumoral drug retention.
    Ma J; Chen CS; Blute T; Waxman DJ
    Cancer Res; 2011 Apr; 71(7):2675-85. PubMed ID: 21447737
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent.
    Pedley RB; Sharma SK; Boxer GM; Boden R; Stribbling SM; Davies L; Springer CJ; Begent RH
    Cancer Res; 1999 Aug; 59(16):3998-4003. PubMed ID: 10463598
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human amniotic fluid-derived stem cells expressing cytosine deaminase and thymidine kinase inhibits the growth of breast cancer cells in cellular and xenograft mouse models.
    Kang NH; Hwang KA; Yi BR; Lee HJ; Jeung EB; Kim SU; Choi KC
    Cancer Gene Ther; 2012 Jun; 19(6):412-9. PubMed ID: 22498724
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasmin-activated doxorubicin prodrugs containing a spacer reduce tumor growth and angiogenesis without systemic toxicity.
    Devy L; de Groot FM; Blacher S; Hajitou A; Beusker PH; Scheeren HW; Foidart JM; Noël A
    FASEB J; 2004 Mar; 18(3):565-7. PubMed ID: 14734647
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.